Brief: Pharnext announces DSMB recommends continuing the ongoing Phase 3 trial of PXT3003
06/09/2017 16:46
Sept 6 (Reuters) - PHARNEXT SAS PHARN.PA :
* ANNOUNCES THAT THE DSMB RECOMMENDS CONTINUING THE ONGOING
PHASE 3 TRIAL OF PXT3003 FOR CHARCOT-MARIE-TOOTH DISEASE TYPE 1A
* WE LOOK FORWARD TO COMPLETING THIS CLINICAL TRIAL AND
SHARING TOP-LINE RESULTS IN MID-2018
Source text for Eikon: ID:nBw2bS1LMa
Further company coverage: PHARN.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Pharnext SCA
See all newsBrief: Pharnext Progresses On Charcot-Marie-Tooth Disease Study
Brief: Pharnext Reports Topline Results From Pivotal Phase III Clinical Trial Of PXT3003 In Charcot-Marie-Tooth Disease Type 1A
Brief: Pharnext Receives Offer Valuing Its Drug Candidate For Charcotmarie-Tooth Disease At Over Eur 500 Mln
Brief: Pharnext Appoints Dr Gilbert Wagener As Chief Medical Officer
Brief: Pharnext Reports Significant Progress In Search For Pharmaceutical Partners To Finance Its Development